glp 1 age restrictions GLP-1 use peaks in middle age, then drops at 65 Thank you to @thedailybeast and

In the most recent American Association of Clinical Endocrinology clinical practice guidelines for the diagnosis and management of NAFLD it was recommended to administer pioglitazone (PIO) or glucagon-like peptide 1 receptor (GLP-1R) agonists with proven benefit for patients with T2D and biopsy-proven NASH, while these medications should be considered when there is high probability of having NASH (based on higher plasma aminotransferase levels and non-invasive tests) [40]

Our goal is to help patients understand their treatment options and determine whether GLP-1 medications, Tirzepatide, Semaglutide, or other medical weight loss treatments may be appropriate based on their individual health goals and provider evaluation

MQ: Writing review & editing, Writing original draft

Many participants lost an average percentage of their body weight similar to early-stage GLP-1 injection trials, which is why experts believe it may emerge as a major rival to injectable GLP-1 receptor agonists

Regarding HbA1c levels, retatrutide showed lower levels than those in the db/db group